The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells1

Aluminum hydroxide (alum) and the oil-in-water emulsion MF59 are widely used, safe and effective adjuvants, yet their mechanism of action is poorly understood. We assessed the effects of alum and MF59 on human immune cells and found that both induce secretion of chemokines, such as CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), and CXCL8 (IL-8), all involved in cell recruitment from blood into peripheral tissue. Alum appears to act mainly on macrophages and monocytes, whereas MF59 additionally targets granulocytes. Accordingly, monocytes and granulocytes migrate toward MF59-conditioned culture supernatants. In monocytes, both adjuvants lead to increased endocytosis, enhanced surface expression of MHC class II and CD86, and down-regulation of the monocyte marker CD14, which are all phenotypic changes consistent with a differentiation toward dendritic cells (DCs). When monocyte differentiation into DCs is induced by addition of cytokines, these adjuvants enhanced the acquisition of a mature DC phenotype and lead to an earlier and higher expression of MHC class II and CD86. In addition, MF59 induces further up-regulation of the maturation marker CD83 and the lymph node-homing receptor CCR7 on differentiating monocytes. Alum induces a similar but not identical pattern that clearly differs from the response to LPS. This model suggests a common adjuvant mechanism that is distinct from that mediated by danger signals. We conclude that during vaccination, adjuvants such as MF59 may increase recruitment of immune cells into the injection site, accelerate and enhance monocyte differentiation into DCs, augment Ag uptake, and facilitate migration of DCs into tissue-draining lymph nodes to prime adaptive immune responses.

[1]  Clare L. Bennett,et al.  Lipopolysaccharide or Whole Bacteria Block the Conversion of Inflammatory Monocytes into Dendritic Cells In Vivo , 2003, The Journal of experimental medicine.

[2]  J C Gluckman,et al.  Dendritic cells as the terminal stage of monocyte differentiation. , 1998, Journal of immunology.

[3]  Giuseppe Del Giudice,et al.  MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile , 2003, Expert review of vaccines.

[4]  A. Rostami,et al.  Demonstration and phenotypic characterization of resident macrophages in rat skeletal muscle. , 1990, Immunology.

[5]  Marc Dupuis,et al.  Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis , 2001, European journal of immunology.

[6]  N. Valiante,et al.  Recent advances in the discovery and delivery of vaccine adjuvants , 2003, Nature Reviews Drug Discovery.

[7]  K. Heeg,et al.  Involvement of suppressors of cytokine signaling in toll-like receptor-mediated block of dendritic cell differentiation. , 2006, Blood.

[8]  B. Beutler,et al.  Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling , 2006, Science.

[9]  D. McDonald,et al.  Dendritic cells internalize vaccine adjuvant after intramuscular injection. , 1998, Cellular immunology.

[10]  A. Podda The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. , 2001, Vaccine.

[11]  M. Singh,et al.  MF59: A Safe and Potent Adjuvant for Human Use , 2006 .

[12]  R. Steinman,et al.  Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. , 1998, Science.

[13]  J. Kinoshita Women Fight Uphill Battle for Equity , 1996, Science.

[14]  M. Grounds,et al.  Macrophages and dendritic cells in normal and regenerating murine skeletal muscle , 1997, Muscle & nerve.

[15]  D. Charron,et al.  TLR7/8 agonists impair monocyte‐derived dendritic cell differentiation and maturation , 2007, Journal of leukocyte biology.

[16]  T. Luft,et al.  Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. , 2002, Blood.

[17]  V. Schijns Immunopotentiators in modern vaccines , 2003 .

[18]  C. Janeway,et al.  Innate Immunity: The Virtues of a Nonclonal System of Recognition , 1997, Cell.

[19]  R. Gupta,et al.  Adjuvant properties of aluminum and calcium compounds. , 1995, Pharmaceutical biotechnology.

[20]  Grégoire Altan-Bonnet,et al.  Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell–dendritic cell interaction , 2006, Nature.

[21]  D. Dormont,et al.  Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. , 2004, Vaccine.

[22]  Manmohan J. Singh,et al.  A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. , 2006, Vaccine.

[23]  S. Gordon,et al.  Monocyte and macrophage heterogeneity , 2005, Nature Reviews Immunology.

[24]  T. Curiel,et al.  Macrophage-Derived Dendritic Cells Have Strong Th1-Polarizing Potential Mediated by β-Chemokines Rather Than IL-121 , 2000, The Journal of Immunology.

[25]  D. Fearon Seeking wisdom in innate immunity , 1997, Nature.

[26]  J. Rodríguez-Fernández,et al.  The Multiple Personalities of the Chemokine Receptor CCR7 in Dendritic Cells1 , 2006, The Journal of Immunology.

[27]  A. Podda,et al.  MF59 Is a Safe and Potent Vaccine Adjuvant for Flu Vaccines in Humans: What Did We Learn During Its Development? , 2007, Clinical pharmacology and therapeutics.

[28]  M. Görner,et al.  Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells. , 2004, Blood.

[29]  R. Locksley,et al.  The Instructive Role of Innate Immunity in the Acquired Immune Response , 1996, Science.

[30]  P. Clayette,et al.  In vitro interactions between macrophages and aluminum-containing adjuvants. , 2007, Vaccine.

[31]  G. Ott,et al.  Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. , 1997, Molecular medicine today.

[32]  Robert V Farese,et al.  Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. , 1997, The Journal of clinical investigation.

[33]  J. Banchereau,et al.  IL-6 switches the differentiation of monocytes from dendritic cells to macrophages , 2000, Nature Immunology.

[34]  G. Zlabinger,et al.  Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. , 1985, Clinical and experimental immunology.

[35]  M. Alderson,et al.  TLR4 agonists as immunomodulatory agents , 2006, Journal of endotoxin research.

[36]  K. Palucka,et al.  Lipopolysaccharide can block the potential of monocytes to differentiate into dendritic cells , 1999, Journal of leukocyte biology.

[37]  M. Ulanova,et al.  The Common Vaccine Adjuvant Aluminum Hydroxide Up-Regulates Accessory Properties of Human Monocytes via an Interleukin-4-Dependent Mechanism , 2001, Infection and Immunity.

[38]  D. McDonald,et al.  Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. , 1999, Vaccine.

[39]  P. Marrack,et al.  Promotion of B Cell Immune Responses via an Alum-Induced Myeloid Cell Population , 2004, Science.